Summary: The success of checkpoint blockade cancer immunotherapies has unequivocally confirmed the critical role of T cells in cancer immunity and boosted the development of immunotherapeutic strategies targeting specific antigens on cancer cells. The vast immunogenetic diversity of human leukocyte antigen (HLA) class I alleles across populations is a key factor influencing the advancement of HLA class I–restricted therapies and related research and diagnostic tools.

中文翻译：

---

免疫遗传多样性和癌症免疫治疗差异

摘要：检查点阻断癌症免疫疗法的成功明确证实了 T 细胞在癌症免疫中的关键作用，并促进了针对癌细胞特定抗原的免疫治疗策略的发展。人类白细胞抗原 (HLA) I 类等位基因在不同人群中存在巨大的免疫遗传多样性，是影响 HLA I 类限制性疗法及相关研究和诊断工具进步的关键因素。